Deutsche Bank sees more than a 30% rally for this specialty biotech stock

  • 📰 CNBC
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 72%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

Deutsche Bank upgraded Catalent on Monday to buy from hold as the company's partnership with Moderna could help it grow market share.

Deutsche Bank is more bullish on Catalent after the New Jersey-based company expanded its manufacturing partnership with Moderna . Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. That represents more than 30% upside for investors, based on Monday's closing price of $67.26.

mountain Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share. He added that Catalent stock, which gained 3.6% on the back of the upgrade, has already outperformed the S & P 500 this year with a gain of 49% compared with the key index's 7% advance. Bowers said he anticipates more upside ahead.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

30 best global stock picks to buy now: How to beat the market, RBCRBC: Buy these 30 high-conviction stocks as they continue delivering market-beating returns in an up-and-down year
Source: BusinessInsider - 🏆 729. / 51 Read more »